Roche/Ionis Sefaxersen Cuts Proteinuria 43.1% in Phase 3 IgAN Trial
IONS is trading near its 52-week low of $42.08 (2.0% above the low) on light trading volume (0.4× avg).
Summary
In Roche's Phase 3 IMAgINATION study, Ionis-discovered sefaxersen cut proteinuria 43.1% versus placebo at 37 weeks (P<0.0001), with clean safety and consistent subgroup results. Roche will take the data to regulators; Ionis collects milestones and tiered royalties rather than direct sales.
Key Events · Product Development and Regulatory · IONS
-
Sefaxersen Hits Primary Endpoint
At 37 weeks, Phase 3 IMAgINATION delivered a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% CI: 32.5-52.0, P<0.0001) versus placebo, measured by 24-hour UPCR.
-
Clean Safety, Consistent Subgroups
The treatment effect held across all prespecified subgroups, matching the primary endpoint, and sefaxersen was well tolerated, with a safety profile consistent with the prior Phase 2 study and no new safety signals.
-
Roche to Engage Regulators
Roche will share the data with health authorities with the goal of bringing the treatment to patients as soon as possible; sefaxersen is an investigational once-monthly subcutaneous self-administered injection.
-
Ionis Economics Are Royalty-Based
An upfront payment, license fee and development milestones have already been received by Ionis, which is eligible for regulatory and sales milestones plus tiered royalties on net sales of sefaxersen.
Analysis · IONS · Life Sciences
What matters here is that the full Phase 3 IMAgINATION dataset confirms sefaxersen's 43.1% proteinuria reduction at 37 weeks (P<0.0001), with consistent effects across all prespecified subgroups and no new safety signals. Results of that caliber support a regulatory filing, and Roche says it will share the data with health authorities. Ionis does not book sefaxersen revenue directly; it has already received upfront, license and development milestone payments and stands to collect regulatory and sales milestones plus tiered royalties on net sales. The value, then, is a de-risked royalty stream rather than near-term cash, which is why the stock reaction may be more measured than the headline number suggests. One binary item remains: the blinded two-year eGFR readout at week 105, which will determine whether the proteinuria benefit translates into preserved kidney function.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 29.4% of the 1556 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IONS was trading at $42.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $42.08 to $86.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.